New findings from our research showed that the low-dose spironolactone can reduce myocardial hypertrophy and deposition of cardiac chamber collagen fibers and decrease susceptibility to atrial fibrillation by reducing the expression of atrial TGF-β1; different doses of spironolactone group had a certain dose-dependence. Here, TGFB1 is linked to cardiac hypertrophy.